ABL1 Kinase Domain Mutation Analysis | NeoGenomics Laboratories

Code

MOG-AKDX-01BV

Test

Active-Compendium

81170

Clinical

Oncology,Pathology

Bone Marrow Aspirate: 2 mL in EDTA tube. 
Peripheral Blood: 5 mL in EDTA tube. 
Note: Test is RNA-based. Please select Extract & Hold - RNA if specimen hold service is desired.

Hematologic Diseases

Acute lymphoblastic leukemia (ALL)

Chronic myeloid leukemia (CML)

Mon, 01/13/2025 - 12:00

Sat, 12/06/2025 - 12:00

Molecular

Global

Flag Active

True

Orderable Test Description

This test uses RT-PCR and sequencing to detect BCR-ABL1 fusion transcript mutations associated with resistance to Gleevec (imatinib) and other tyrosine kinase inhibitors. 

Includes analysis of common mutations like T315I, Y253H, E255K/V, F359V/C/I, F317L/V/I/C, T315A, and V299L.

Orderable Turn Around Time

10 Days

Keywords

Kinase Domain Mutation

T315I

Mutation Analysis

Meta Description

RT-PCR and sequencing of the BCR-ABL1 fusion transcript for qualitative detection of mutations associated with resistance to Gleevec (imatinib) and other tyrosine kinase inhibitors. Analysis includes detection of the common T315I mutation.

Hematologic disease

Orderable Biomarkers

ABL1

NY Approved

True

Orderable Biomarkers JSON

{"DNA Sequencing": {"SNVs + Indels": ["ABL1"]}}

Keywords string

ABL1, BCR-ABL, BCR/ABL1, BCR-ABL1, Kinase Domain Mutation, T315I, Mutation Analysis ABL1 Kinase Domain Mutation Analysis

Title URL

abl1-kinase-domain-mutation-analysis

Clinical Significance

Mutations within the BCR-ABL1 kinase domain of patients with chronic myeloid leukemia or acute lymphoblastic leukemia with Philadelphia chromosome are the most commonly identified mechanism associated with resistance to kinase inhibitors. It has been reported that most patients with detectable BCR-ABL1 kinase domain mutations are imatinib resistant or resistant to other kinase inhibitors.

This assay includes analysis for T315I, the most commonly reported imatinib resistance mutation, which is also resistant to two second generation tyrosine kinase inhibitors, nilotinib and dasatinib. Failure to achieve cytogenetic response in the first 6 months of therapy in CML patients often reflects the presence of mutations or a high probability that mutations will subsequently be detected.

Storage and transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible. NYS clients please provide date and time of collection. Please select Extract & Hold - RNA if specimen hold service is desired.